Deep Tech Startups

Oversight develops a collaborative edge-AI operating system for critical operations, supporting mission planning, training, live execution, and debrief for military and law enforcement units. Its platform uses data fusion, computer vision, and AI-driven insights, and has been used by IDF and police special operations forces.

1 investor

Ovomind builds an end-to-end platform that converts biosignals from a patented smartband into real-time emotional data, delivered via SDKs and a cloud AI engine for companies to create emotion-aware products, services, and interfaces. It serves hardware makers, product designers, and developers across sectors such as mobility, wellness, and entertainment, and offers hardware and software licensing of its patented biosensing architecture.

1 investor

OXECO is an Oxford University spin-out that develops ultra-thin functional coatings using its ONTO™ surface-modification chemistry based on reactive carbenes applied via wet coating techniques. It serves manufacturers in purification, bioprocessing, and high-value manufacturing to enhance material surface performance.

1 investor

Oxford Investment Opportunity Network (OION) is a business angel network that connects investors with early-stage, high-growth UK companies eligible for EIS or SEIS tax relief. The network facilitates pre-screened investment opportunities across sectors including deep tech, AI, life sciences, and clean tech, with typical deal sizes between £100,000 and £2,000,000.

1 investor

Oxford nanoSystems (OnS) develops coating technologies that improve electrolysers and heat exchangers, allowing them to be smaller, lighter, more efficient and lower cost. The company focuses on coatings for alkaline water electrolysers to produce hydrogen more efficiently for clean energy applications.

1 investor

Oxford Semantic Technologies develops RDFox, an in-memory knowledge graph and semantic reasoning engine that uses logic-based inference to deduce new facts and deliver explainable, auditable results for AI applications. It targets enterprises needing high-performance, scalable knowledge graphs, with a footprint compact enough to be embedded on edge and mobile devices.

1 investor

OzAmmonia develops a patented multiphase electrolyser that converts NOx emissions into green ammonia at ambient conditions, offering industry an electrified pathway for NOx abatement without chemical reagents. The technology targets industrial emitters seeking lower-cost waste NOx treatment and is suited to combustion of future fuels such as hydrogen and ammonia.

1 investor

P3 Therapeutics is developing a new class of anti-inflammatory small chemical molecules and works with partners on a humanized gut-entheseal organ-on-chip platform to study their mechanism of action, pharmacokinetics, pharmacodynamics, and biomarkers. The work is part of an application to the EUROSTARS 3 program under the TRIGG3R project.

1 investor

Pacific Biosciences manufactures consumables and reagent kits for long-read DNA and RNA sequencing platforms, serving genomics research and diagnostics labs.

1 investor

Packet Digital develops power systems and power management technologies for autonomous systems operating in air, sea, land, and space, including unmanned aircraft and solar products. It also provides engineering services and embedded software work for these applications.

1 investor

PAL Italy is a robotics company specializing in research, development, and deployment of robotic systems for industrial and healthcare applications in Italy. The company serves Italian industries and healthcare sectors facing labor shortages through automation research, platform distribution, and real-world robot implementation.

1 investor

Palisade builds an AI security module that attaches to the Linux kernel via LSM-BPF to detect operating-system vulnerabilities—such as privilege escalation, remote code execution, and memory corruption—and deploy vetted fixes as kernel-enforced rules across an entire fleet. It targets organizations running GPU clusters, cloud device fleets, and on-device endpoints.

1 investor

Palm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules. The company focuses on modulating protein palmitoylation, a post-translational modification involved in multiple disease pathways.

1 investor

Pangaea Ventures is a venture capital firm that invests in hard tech companies working in materials science, chemistry, and biology to address environmental and planetary challenges. It has backed over 40 ventures and operates with an impact model aligned to the UN Sustainable Development Goals.

1 investor

Pangolin Therapeutics develops Pangomers, synthetic molecules designed to target and interfere with intrinsically disordered proteins involved in Type 2 Diabetes, neurodegeneration, and cancer. The company uses molecular modeling and drug discovery tools to create therapeutics for previously undruggable protein targets.

1 investor

panluminate develops instruments and processes for whole-brain connectomic mapping at scale, using its pan-ExM imaging technique to capture both neural wiring and molecular state simultaneously at 15nm resolution. It serves neuroscience research institutions with products and services that combine high-resolution microscopy and AI-based segmentation of brain circuitry.

1 investor

Panthura develops non-viral DNA delivery technology for sustained therapeutic effects in specific tissues, with potential for repeated administration. The company is advancing its platform through preclinical and clinical development stages.

1 investor

Papcup develops a non-invasive cervical screening platform using electrochemical biosensing technology to provide faster, more accessible diagnostics. The company targets women seeking cervical cancer screening and aims to expand its biosensor-based approach across broader healthcare diagnostics.

1 investor

Paragon provides instrumentation and control (I&C) life-cycle management for nuclear power plants, including third-party component repair, reverse engineering, and digital system replacements. It serves nuclear facility operators seeking alternatives to costly OEM upgrades to extend the life of aging I&C assets.

1 investor

Parallel Venture Capital is an early-stage investment firm that backs U.S. and allied-founded startups developing dual-use technologies serving both government and commercial customers. It focuses on defense and national security applications, connecting portfolio companies to the Department of Defense, Intelligence Community, and allied partners.

1 investor

Paralos is developing a modular M13 phage drug delivery platform that creates phage-drug conjugates to concentrate therapeutic payloads at specific targets. The platform pairs programmable target binding with payload presentation to localize drug exposure and engineer delivery around the therapeutic window.

1 investor

Paras Aqua develops land-based aquaculture systems focused on fish welfare and sustainable production. The company offers the Paras Precision Hybrid Flow-through System, a patented technology that improves water reuse, operational efficiency, and profitability for fish farming facilities.

1 investor

Pareon Biosystems has developed a multiplex biomarker quantification method that produces absolute measurements with built-in correction for non-specific binding. The approach uses low concentrations of common reagents and standard lab equipment such as PCR, targeting personalized/precision medicine applications in research and clinical settings, including resource-limited environments.

1 investor

Parkway VC is a venture capital firm that invests in early and mid-stage companies across technology, sustainable energy, and disruptive innovations, with a focus on scaling high-growth ventures. The firm's team brings deep entrepreneurial and operational expertise, with partners holding experience from major financial institutions and successful exits across multiple sectors.

1 investor